NCT01449006 - A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Human Immunodeficiency Virus (HIV)HIV Associated Neurocognitive Disorders (HAND)

Interventions

DRUG

Maraviroc

Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.

Trial Locations (2)

2010

St. Vincent's Hospital, Sydney

3181

The Alfred Hospital, Melbourne